BPC-157 vs TB-500

BPC-157 is a synthetic peptide based on a stomach juice protein, and TB-500 is a short synthetic fragment of thymosin beta-4. Neither is approved, both are banned in sport, and almost all study results for both come from animal and lab studies. This page compares their results.

Best randomized result by outcome

For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.

No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.

Comparing 2 peptides · Data version 308560

Only differences

Swipe sideways to see every peptide.

Comparison of BPC-157, TB-500
Peptide	Synthetic fragment BPC-157	Synthetic fragment TB-500
Identity
Kind	Synthetic fragment	Synthetic fragment
Area	Recovery and repair	Recovery and repair
Evidence
Amount of evidence	987	36
Evidence level	Has results from studies in people	Results from animal studies onlyRegistered trials, no results from human studies
Safety
Safety results	24 (8 in people)	1 (0 in people)
Status
Approval
Sport (WADA)
Registered trials	3 · 2 active1 more mentions it but does not test it	1 · 1 active

Shared outcomes

Wound healing138
Neuroprotection82
Tendon and ligament healing54
Adverse events25
Inflammation markers45
Pharmacokinetics13
Cognition and memory4

Approval and sport status

From the regulatory data of each peptide.

BPC-157
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 30 Oct 2026).
TB-500
Its most advanced trial is in phase 1. The FDA, the EMA and the other sources we use show no approval (as of 30 Oct 2026).

Amount of evidence by outcome

Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.

Study results per shared outcome group and evidence class
Outcome group	BPC-157	TB-500
Wound healingSkin and wound	1301228	826
NeuroprotectionNervous system and cognition	7474	853
Tendon and ligament healingMusculoskeletal	463511	88
Adverse eventsWhole body	24816	11
Inflammation markersWhole body	4141	413
PharmacokineticsPharmacology	871	541
Cognition and memoryNervous system and cognition	22	22

Sequence alignment

Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.

Against Thymosin beta-4 (human)TB-500

TB-500 is the same as Thymosin beta-4 (human) residues 17 to 23, with 1 added group.

Top row: Thymosin beta-4 (human) (parent)
Bottom row: TB-500

KKTET

Same as parent
Substituted
Non-canonical or D-form
Modified side chain or end
Parent context

What is different

1Position 17: Leu carries an added group: N-terminal acetyl.

Trials side by side

Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.